BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases
On Dec. 19, 2025, BioMarin Pharmaceutical and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement…
-
-
Amicus Therapeutics announced FDA approval and launch of treatment for Pompe disease
On Sept. 28, 2023, Amicus Therapeutics’ treatment for a rare muscle disorder called Pompe disease was approved by…
-
FDA approved new treatment for Pompe Disease
On Aug. 6, 2021, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Nexviazyme® (avalglucosidase alfa-ngpt) for the…
